Fentanyl TAIFUN® is a fast-acting fentanyl formulation delivered using LAB International Inc. (TSE: LAB)’s TAIFUN® dry powder inhaler platform.
The company has recently announced the positive results from its open-label Phase IIb clinical trial of Fentanyl TAIFUN® which demonstrated successful dose titration resulting in effective control of breakthrough pain episodes.
The Fentanyl TAIFUN® doses used in the study have been highly tolerated in opioid tolerant cancer patients.
According to Dr. Halvor Jaeger, Chief Executive Officer of LAB International:
Find more details from the press release."We are extremely pleased with the strong results from the open-label arm of our Fentanyl TAIFUN® Phase IIb clinical trial. They clearly demonstrate once again the superior formulation, technological platform and therapeutic profile of our lead compound.
In order to maintain and strengthen our leading position among inhaled fentanyl developers, we have filed a new patent application on the product, making it more difficult for followers to imitate our unique clinical profile."
Yes, only clearly demonstrate :(
Posted by: Vaigra | July 20, 2007 1:43 AM | Permalink to Comment